2010 Portfolio Company News

December 14, 2010

VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss Qnexa

October 28, 2010

FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for Qnexa

October 1, 2010

Sunesis Prices $15.5 Miillion Offering

September 21, 2010  

New Long-Term Data On Qnexa® Show Significant And Sustained Weight Loss Of Greater Than 10% Over Two Years

September 21, 2010

Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing

June 30, 2010

Sunesis Closes $28.5 Million Final Tranche of 2009 Private Placement

June 7, 2010

Sunesis Announces Data From Phase 2 Clinical Program of Voreloxin in Acute Myeloid Leukemia Support Phase 3 Trial in Relapsed or Refractory Patients

March 26, 2010

VIVUS Announces Date of FDA Advisory committee Review of Qnexa (R) for the Treatment of Obesity

March 15, 2010

Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference

March 1, 2010

Gentium Announces Management Changes and Corporate Restructuring

January 11, 2010

Gentium Announces Extension of License and Supply and cost Sharing Agreements with Sigma- Tau

January 11, 2010

VIVUS Announces Additional Results of Phase 3 avanafil Study in Erectile Dysfunction Showing Efficacy in 15 Minutes

January 7, 2010

VIVUS Announces Positive Results From Phase 2 Study of Qnexa in Obstructive Sleep Apnes